DD on $ASEP following its IPO on the CSE! Today, ASEP Medical Holdings ($ASEP) commenced trading on the CSE!
ASEP is a biotechnology company focused on the unmet medical needs in major areas related to Sepsis. ASEP offers a rapid and effective way to identify and treat Sepsis, a life-threatening reaction to an infection.
"Our purpose is to mitigate the global crisis of antibiotic failure by improving patients’ odds of survival and quality of life."
Background on Sepsis:
- Sepsis is one of the move prevalent cases of death in the US
- 49M people/year develop sepsis
- 11M people/year die
- #1 complication in hospitalized covid-19 patients
Current industry tests require 24 hours for results to detect and confirm Sepsis. However, ASEP tests are confirmed within 1 hour and can be used to both treat and prevent Sepsis by detecting a unique gene expression profile highly associated with Sepsis and organ failure.
ASEP's majority-owned subsidiaries & technologies:
- ABT Innovations: Offers treatment for a broad range of infectious diseases
- Sepset Biosciences: Offers a diagnostic kit for predicting the onset of severe Sepsis and organ failure
ASEP is a consolidation of two technologies offering both diagnostic and therapeutic products
- Diagnostics: Test to identify unique genetic markers related to an immune dysfunction resulting from infections leading to the onset of Sepsis
- Therapeutics: Patented pharmaceutical peptide that uniquely targets biofilm infections and inflammation
ASEP's current study:
- Largest ever predictive clinical geometrics study of early SEPSIS to validate diagnostic tests
- 500 patient clinical study worldwide
- Enable extrapolation to additional patient populations (ex. Covid-19, cancer, pediatrics, etc.)
The Market:
Tapping into the antibiotic resistance market, one that is full of unmet needs as there are no approved treatments for biofilms, ASEP is working to directly address the lack of approved medicines for common biofilm infections.
To do so, ASEP has developed a proprietary Peptide Technology applied as an early medical intervention to prevent biofilm growth and reduce inflammation.
Investment highlights:
- Large addressable global markets: Unmet needs with no clinical solutions
- Novel technologies: Early diagnostic and treatment
- Extensive intellectual property: Portfolio with both diagnostic and therapeutic applications
- Near-term revenue models
- Experienced management team
The low valuation of ASEP is notable, 60.6mm OS at $0.50/share = ~$30mm market cap relative to peers demanding million and billions of dollar valuations.
Plus, ASEP has raised around $15M in grants, keeping dilution low.
ASEP is looking really promising IMO. Its commercialization is expected in the middle of 2022 and I'm thinking it'll be a major hit.
News Release: https://ca.news.yahoo.com/asep-medical-announces-listing-canadian-130000339.html
Website: https://asepmedical.com/about/